Cargando…
Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)(n) Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?
To ensure accuracy of UGT1A1 (TA)(n) (rs3064744) genotyping for use in pharmacogenomics-based irinotecan dosing, we tested the concordance of several commonly used genotyping technologies. Heuristic genotype groupings and principal component analysis demonstrated concordance for Illumina sequencing,...
Autores principales: | Sissung, Tristan M., Barbier, Roberto H., Price, Douglas K., Plona, Teri M., Pike, Kristen M., Mellott, Stephanie D., Baugher, Ryan N., Whiteley, Gordon R., Soppet, Daniel R., Venzon, David, Berman, Arlene, Rajan, Arun, Giaccone, Giuseppe, Meltzer, Paul, Figg, William D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037496/ https://www.ncbi.nlm.nih.gov/pubmed/32019188 http://dx.doi.org/10.3390/ijms21030896 |
Ejemplares similares
-
Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer
por: Sissung, Tristan M., et al.
Publicado: (2019) -
UGT1A1 (TA)(n) Promoter Genotype: Diagnostic and Population Pharmacogenetic Marker in Serbia
por: Vukovic, M, et al.
Publicado: (2018) -
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
por: Jain, Lokesh, et al.
Publicado: (2010) -
Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain
por: Bravo-Gómez, Adrián, et al.
Publicado: (2022) -
Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression
por: Pressler, Heather, et al.
Publicado: (2011)